ISRCTN78428828 https://doi.org/10.1186/ISRCTN78428828

Neonatal Insulin Replacement Therapy in Europe

Submission date	Recruitment status
30/09/2004	No longer recruiting
Registration date	**Overall study status**
30/09/2004	Completed
Last Edited	**Condition category**
03/06/2014	Nutritional, Metabolic, Endocrine

[_] Prospectively registered
[X] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof David B Dunger

Contact details
Box No 116
University Dept of Paediatrics
Addenbrooke's NHS Trust
Hills Road
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 336886
dbd25@cam.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0544112291 (pilot study reference on NRR)

Study information

Scientific Title

Acronym
NIRTURE

Study objectives
It is proposed that relative insulin deficiency in the very low birth weight baby leads to profound catabolism, insulin resistance and hyperglycaemia during the first week of life. High blood glucose levels may lead to osmotic diuresis, intraventricular haemorrhage and increase the risk of sepsis. Insulin deficiency may contribute to slow weight gain and impaired IGF-I generation which could have implications for risk of retinopathy, brain growth and later neurodevelopmental outcomes. It is hypothesised that early intervention with continuous insulin replacement will prevent catabolism and improve glucose control, and could reduce neonatal morbidity and mortality.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Prevention

Participant information sheet

Health condition(s) or problem(s) studied
Nutritional, Metabolic, Endocrine: Hyperglycaemia

Interventions
Intervention: Insulin aspart (NovoNordisk) for intravenous injection. Insulin will be given intravenously at a fixed rate of 0.05 u/kg/hour. It will be prepared as a standard strength solution of 25 units/kg insulin aspart in 50 ml of 0.9% sodium chloride to run at 0.1 ml/hour, equivalent to 0.05 u/kg/hour.

The control intervention will be standard neonatal care.

All babies will be monitored using the Minimed continuous glucose monitoring system (CGMS) for 7 completed days.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Insulin

Primary outcome measure
Death on or before expected date of delivery.

Secondary outcome measures
1. Episodes of sepsis in the first 2 weeks
2. Growth
3. Incidence of necrotizing enterocolitis
4. Retinopathy of prematurity
5. Incidence of intracranial haemorrhage
6. Chronic lung disease
7. Death within and including the first 28 days after delivery
8. Days of Neonatal Intensive Care

Overall study start date
25/04/2002

Completion date
01/01/2008

Eligibility

Key inclusion criteria
1. Birth weight <1500 g
2. Requiring intensive care and in whom it is considered appropriate to continue intensive care
3. Less than 24 hours of age
4. Written informed parental consent

Participant type(s)
Patient

Age group
Neonate

Sex
Both

Target number of participants
500

Key exclusion criteria
1. Maternal diabetes including gestational diabetes
2. Babies where the appropriateness of continuing intensive care is being discussed
3. Major congenital anomalies

Date of first enrolment
25/04/2002

Date of final enrolment
01/01/2008

Locations

Countries of recruitment
Belgium

England

Netherlands

Spain

United Kingdom

Study participating centre
Box No 116
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation
Cambridge University Hospitals NHS Foundation Trust (UK)

Sponsor details
R&D Department
Box 146
Hills Road
Cambridge
England
United Kingdom

CB2 2QQ
+44 (0)1223 596377
sabine.klager@addenbrookes.nhs.uk

Sponsor type
Hospital/treatment centre

Website
http://www.addenbrookes.nhs.uk

ROR
https://ror.org/04v54gj93

Funder(s)

Funder type
Industry

Funder Name
Medtronic and Novonordisk

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	10/08/2007		Yes	No
Results article	results	30/10/2008		Yes	No
Results article	results	01/05/2014		Yes	No